Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 5/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 3/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.31 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16773178 | 0.86 | AKT1 (0.32) | AKT1P2RY12ITGB3ITGA2BAKT2 | |
| SCHEMBL16773363 | 0.86 | P2RY12 (0.32) | AKT1P2RY12ITGB3ITGA2BAKT2 | |
| SCHEMBL30776945 | 0.78 | KIT (0.47) | HTT | |
| SCHEMBL30776941 | 0.78 | KIT (0.47) | HTT | |
| SCHEMBL15390338 | 0.78 | KIT (0.47) | HTT | |
| SCHEMBL25265377 | 0.75 | FFAR1 (0.37) | — | |
| SCHEMBL16626887 | 0.75 | FFAR1 (0.37) | — | |
| SCHEMBL16773487 | 0.75 | MTNR1B (0.32) | AKT1P2RY12AKT2AKT3 | |
| SCHEMBL29165557 | 0.74 | MTNR1B (0.37) | HTTAKT1P2RY12AKT2AKT3 | |
| SCHEMBL29165554 | 0.74 | MTNR1B (0.37) | HTTAKT1P2RY12AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | HTT 1378/4885AKT1 24/4885P2RY12 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.